GLP-1 agonists associated with reduced hepatic decompensation and mortality in older adults with MASLD, cohort study
Retrospective cohort study of 43,930 adults aged ≥65 years with metabolic dysfunction-associated steatotic liver disease (MASLD), comparing GLP-1 receptor agonist initiators to unexposed patients using propensity-score matching. GLP-1 RA use was associated with lower hazards of hepatic decompensation (HR 0.72), mortality (HR 0.55), and hospitalisation (HR 0.95), but showed no reduction in major adverse cardiovascular events (HR 0.98). Increased rates of gastrointestinal events, osteoporosis without fracture, and retinopathy were observed in the GLP-1 RA group.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 4, 2026 · Discovered: Sep 21, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Cohort
- Sample size
- 43,930
- Duration
- 120 months
- Population
- Adults 65 years or older with metabolic dysfunction-associated steatotic liver disease (MASLD), identified by codes for fatty liver disease or steatohepatitis plus one cardiometabolic risk factor. Excluded liver transplant recipients and other liver disease causes.
- Primary outcome
- Hepatic decompensation
- Effect size
- Hepatic decompensation: HR 0.72 (95% CI 0.66-0.79); Mortality: HR 0.55 (95% CI 0.52-0.58); Hospitalisation: HR 0.95 (95% CI 0.93-0.97); MACE: HR 0.98 (95% CI 0.92-1.04)
- Significance
- Mixed
- Journal
- Age and ageing
- Published
- Sep 4, 2026
Sources
Primary source
- Age and ageing ↗Peer reviewed
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.